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Background: The use of transoral robotic surgery (TORS) and laser microsurgery (TLM) in the diagnosis and
identification of the site of the unknown primary has become increasingly common. This systematic review and
meta-analysis aims to assess the use and efficacy of TORS and TLM for this indication.
Method: Systematic review and meta-analysis of studies employing TORS or TLM in diagnosis of the unknown
primary tumor site in patients with cervical nodal metastases of squamous cell origin. MEDLINE, EMBASE and
CINHAL were searched from inception to July 2018 for all studies that used TORS and or TLM in identifying the
unknown primary.
Results: 251 studies were identified, of which 21 were eligible for inclusion. The primary tumour was identified
by TORS/TLM in 78% of patients (433 out of 556). Tongue base mucosectomy (TBM) identified the primary in
222 of 427 cases (53%). In patients with negative physical examination, diagnostic imaging and PETCT, TBM
identified the primary in 64% (95% CI 50, 79) cases. In patients who had negative CT/MRI imaging, negative
PETCT and negative EUA and tonsillectomy, TBM identified a tongue base primary in 78% (95% CI 41, 92) cases.
Haemorrhage, the commonest complication, was reported in 4.9% cases. Mean length of stay varied between 1.4
and 6.3 days.
Conclusion: Tongue base mucosectomy, performed by TORS or TLM, is highly efficacious in identifying the
unknown primary in the head and neck region.
Introduction
Metastatic cervical lymphadenopathy from an unknown primary
tumour accounts for 2% to 5% of head and neck squamous cell carci-
nomas (HNSCC) [1,2]. The importance of identifying the primary site
lies in minimizing the potential morbidity from treatment by reducing
the radiation field [3]. Although not conclusive, some evidence suggests
that patients with an identified primary may also enjoy better oncologic
outcomes than those with unidentified primaries [4].
The outpatient workup of these patients traditionally involves
taking a thorough history and examination (including flexible naso-
laryngopharyngoscopy) followed by conventional imaging
(Computerised Tomography - CT scan, Magnetic Resonance Imaging –
MRI), and/or Positron Emission Tomography - PETCT). If imaging fails
to identify the site of the primary tumour, then panendoscopy, (+/-
biopsies of the nasopharynx, hypopharynx) tonsillectomy and targeted
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biopsies of the tongue base are usually performed [5]. Despite this,
studies report that the primary tumour still might not be identified in
up to 43% of cases [6].
Transoral Laser Microsurgery (TLM) and Transoral Robotic Surgery
(TORS) of the base of tongue are two modalities that are being in-
creasingly utilised to help identify the site of the primary tumour,
especially in those patients where the site was not identified by con-
ventional and PET CT imaging and/or examination under anesthetic. In
the literature, this is variably described as either lingual tonsillectomy
or tongue base mucosectomy (TBM). Both procedures involve removing
the lymphatic tissue from the base of the tongue and preserving the
underlying musculature. For the purposes of the review, the authors
have considered both terms to be synonymous, but will use TBM within
this paper. The procedure can be performed either as a unilateral or
more commonly as a bilateral procedure.
A systematic review of a small cohort (139 cases) reported success
rates ranging between 84 and 94% using TLM [7,8] and 72–90% using
TORS [5,9–13]. However, it also concluded that the studies were small,
of variable quality and utilised different diagnostic pathways [14].
Since then, several new studies have been published. Our systematic
review incorporates the recent evidence, and therefore includes a much
larger cohort of patients than previously published. We also aim to
explore the efficacy of TBM when used at various points within the
diagnostic pathway following different combinations of diagnostic
modalities.
Methods
Search strategy
The protocol for this systematic review was registered with PROS-
PERO (CRD4201707920). Bibliographic databases (MEDLINE, CINAHL
and Embase) were searched with no language restrictions from incep-
tion to July 2018. Text and index terms relating to the “unknown pri-
mary” and “TORS or TLM” were combined (see Supplementary Table 1
for MEDLINE full search strategy). Reference lists of included studies
were checked. In addition, conference abstracts from the American
Head and Neck Society and European Head and Neck Society annual
meetings for the past 5 years were examined for relevant studies.
Inclusion and exclusion criteria
Primary studies of any study design (case studies, case series and
cross sectional studies) were eligible for inclusion. Studies had to report
on the transoral approach (TORS or TLM) used in identifying the pri-
mary site of head and neck cancers of unknown origin. Human studies
of any language were included. If a case series had been updated, the
most recent version was included. Studies were excluded if they were
animal studies, did not use TORS or TLM or did not report on the lo-
cation of the primary tumour in the head and neck region.
Study selection
All retrieved titles and abstracts were screened by two reviewers
(SF/SK) independently, with disagreements resolved by discussion with
the senior author (HM). Where necessary, full texts were screened. The
study selection process was documented using a PRISMA flow diagram
and reasons for exclusion were noted.
Data extraction
Data extraction was undertaken by two reviewers (SF/SK) using a
piloted data extraction form. Discrepancies were resolved by discussion
with the senior author. Data was extracted on: patient demographics,
study design, pre-operative investigations, identification rate of the
primary site using TORS and/or TLM, post-operative adverse events
and length of stay. All data collected was collated on a Microsoft Excel®
spreadsheet.
Risk of bias assessment
Evaluation of the risk of bias was undertaken by one reviewer (SF)
and checked by a second (SK). Criteria were adapted from the Joanna
Briggs Institute checklists for case reports and case series [15]. These
included items relating to sample selection and description, outcome
selection and reporting and completeness of results.
Synthesis and analysis
All results were tabulated and described narratively. The main
outcome of interest was the proportion of primary tumours identified.
Proportions were presented separately according to type of operation
performed (lingual or palatine tonsillectomy) and the surgical tech-
nique used (TORS or TLM). As studies were deemed to have reasonably
similar patient and study characteristics, the proportions identified
were pooled together, and then separately for TORS and TLM, using a
random effects model in STATA (version 13). Proportions were also
pooled within sub-groups of patients with positive or negative findings
upon preceding investigations. Data in the studies was not reported
according to human papillomavirus status, however we examined
proportions in the subgroup of studies with a reported HPV proportion
of 90% or above. Adverse events and mean length of stay were also
reported. Reporting of results was undertaken according to PRISMA
guidelines [16].
Results
Study selection and characteristics
251 records were identified and screened, of which 21 studies, in-
cluding a total of 556 cases, met the inclusion criteria. The main reasons
for exclusion are detailed in Fig. 1. On full manuscript review, a further
two studies were excluded as three studies were from the same in-
stitution by the same author; and so the most recent of the three studies
was included.
Table 1 summarizes the main study and patient characteristics of
the 21 included studies. The studies were published between 2011 and
2017. The majority (19 of 21) were case series, while two were case
reports. There were no prospective studies. Three studies were multi-
institutional [5,17,25], 16 were from single institutions
[7–12,14,18,19,21–24,27,29] and two studies did not clearly state their
provenance [26,28]
Quality assessments of included studies
All but two studies [9,10] had clear inclusion and exclusion criteria
(Supplementary Table 1). All studies demonstrated evidence of using
valid diagnostic methods of assessing the patient for an unknown pri-
mary prior to the use of TORS or TLM. In all studies, patient selection
was consecutive and based on hospital records. In terms of patient
demographics, there was some significant variation in reporting
amongst the studies. Three studies provided no information on patient
demographics [24,27,28], nine studies provided some information on
age range or gender [8,23] and the remaining provided details on both.
Five of 21 studies did not collect adverse event data [7,23,26,28,29]
Eight studies reported on some complications, but not all the ones
considered to be relevant [5,10,11,19,20,25,27]. Reporting of findings
was based on the complete patient sample in all studies. There was
significant heterogeneity between studies with an I2 statistic of 70.45%,
(p < 0.01).
Patient characteristics
Of the 556 included patients 464 (83%) underwent TORS and 92
(17%) underwent TLM. Based on the 16 studies where relevant in-
formation was reported, the majority of subjects were male (88%) and
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the mean age was 56.6 years. 392 (70.5%) cases were positive for the
Human papillomavirus (HPV). Seventeen studies reported on HPV
status, of which 8 used p16 Immunohistochemistry
[8,17,19–21,24,28,29], 7 studies did not provide any detail of how the
HPV status was reached [5,9,12,18,22,25,26] one study used in-situ
hybridization [11] and another used PCR [14]. Nodal status (according
to the AJCC/UICC TNM 7th edition) was described for 453 patients in
16 studies, and was as follows: N1=108 (24%) N2=31 (7%),
N2a= 110 (24%) N2b=149 (33%) N2c=22 (5%) and 33 (7%) were
N3 [5,7,9–12,14,18–22,24–26,29]
Pre-operative workup
The preoperative work up of patients was described in all but one of
the included studies and is summarised in Table 2. Clinical examination
was a feature of all 21 studies. Panendoscopy and biopsy was performed
in 18 studies [5,7–12,14,17–22,24,25,27,29], and conventional diag-
nostic imaging in the form of CT, MRI or both was undertaken in 9
studies [5,7,9,17,19,20,21,25]. PETCT was used as part of the initial
workup in 18 studies [5,7,9–12,14,17–22,24–29]. There was significant
heterogeneity in the incidence and timing of palatine tonsillectomy
prior to TBM. 11 studies undertook palatine tonsillectomy at the time of
TBM procedure [7–9,11,18–20,22,23,25,29], three before TBM
[12,14,16], three sometimes before and sometimes with the TBM
[5,21,24], and four did not give information [10,26–28].
Identification of the unknown primary
Overall, regardless of timing within the diagnostic pathway, the
proportion of primary tumours identified in the lingual or palatine
tonsil, using either TORS or TLM, was 78% (95% CI 72–84), and ranged
from 57–89% (Table 2 and 3). The pooled proportion identified by
TORS, based on 15 case-series, was 74% (95% CI, 68%, 79%), and by
TLM (based on three studies) was 91% (95% CI 85%, 98%) (see Fig. 2).
The primary tumour site was identified in the tonsil in 31% (16%–
45%) cases (Table 3).
Efficacy of tongue base mucosectomy
The primary tumour site was identified in the lingual tonsil by TBM
in 53% (95% CI 43%, 63%) reported cases, (see Fig.3). This varied by
the type of diagnostic tests that had taken place before TBM in the
diagnostic pathway. In patients with negative physical examination,
diagnostic imaging and PETCT, the tumour site was still identified by
palatine tonsillectomy and/or TBM in 73% of patients. TBM identified
the primary in 64% (95% CI 50, 79) of such cases. In patients who had
negative CT/MRI imaging, negative PETCT and negative EUA and
biopsies [1], TBM identified a tongue base primary in 62% (95% CI 40,
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84) cases. (Table 3in the nine studies (case report excluded) that did
TBM at the same time as palatine tonsillectomy and reported their data,
TBM identified the primary site in 64.2% (95%CI 42, 63) cases. In the
three studies which did palatine tonsillectomy before TBM, the primary
site was identified in the tongue base in 78% (95% CI 41, 92) of cases.
Site of primary tumour identified
Tumours were ipsilateral in 419 (97%) of the cases reporting la-
terality. They were found in the contralateral tongue base in 8 (1.85%)
cases [8,12,21,17,18] and in the contralateral palatine tonsil in one
case (0.23%) case [21]. Bilateral tongue base tumours were identified
in 1 (0.23%) case [11], and bilateral palatine tonsil primaries were
identified in 3 (0.69%) cases [11,20].
Effect of timing of TBM in the diagnostic pathway
Table 3 shows the identification rate by any transoral surgery (pa-
latine and/or TBM) overall, and also by TBM specifically, when used at
various stages of the diagnostic pathway. These are reported according
to whether the preceding investigations were negative or showed sus-
picious findings. Not all studies undertook the same number or type of
investigations, and not all studies fully reported whether patients had
suspicious/non-suspicious findings on one or more different investiga-
tions. Some identification rates are therefore based on only a small
number of studies/patients, particularly for patients with suspicious
findings.
Pooled identification rates in patients with no suspicious findings on
different types of investigations ranged from 69–82% for TORS/TLM;
and 59% to 64% for TBM. The identification rate by transoral surgery
Table 2
Proportion of tumours identified by TORS/TLM overall, by lingual tonsillectomy and by palatine tonsillectomy.
Author Proportion identified by TORS/TLM Proportion identified by lingual tonsillectomy Proportion identified by palatine
tonsillectomy
TORS TLM TORS TLM TORS TLM
Case-series
Mehta 9/10 (90%) 9/10 (90%) _
Channir 7/13 (54%) 7/13 (54%) _
Patel 34/47 (72%) 21/41 (51%) 13/47 (28%)
Winter 17/32 (53%) 17/32 (53%) _
Karni _ 17/18 (94%) 11/18 (61%) 6/18(33%)
Durmus 17/22 (77%) 4/14 (28.5%) 13/17 (76.5%)
Nagel _ 31/36 (86%) 13/19 (68%)
Geltzeiler 37/50 (74%) 32/50 (64%) 5/50 (10%)
Hatten 48/60 (80%) 28/60 (47%) 18/60 (30%)
Graboyes No differentiation made by authors
between TLM and TORS
*61/65
(94%)
27/65 34/65
Byrd 19/22 (86%) 16/22 (73%) 3/22 (13.6%)
Khan/Kass 16/21 (76.1%) _ _
Blanco 1/4 (25%) 0/4 1/4 (25%)
Krishnan 5/7 (71%) 5/7 (71%)
Patel 26/35 (74%) 15 /35(42.9%)
(2 cases with both lingual and
palatine tonsils
+1 case glossotonsillar sulcus)
13/35 (37%)
(2 cases with both lingual
and palatine tonsils)
Khan 48/64 (75%) _ _ _
Wolford 4/9 (44%) 4/9 (44%) _
Newman 10/12 (83%) _
Kuta 25/27 (93%) 12/27(44%) 13/27 (48%)
Case-reports
Abuzeid 1/1 (100%) 1/1 (100%) _
Mourad 0/1 _
Total pooled rate (95%
CI)*
74% (0.68%, 0.79%) 91% (85%,
97%)
53% (43%, 63%) 57% (43%,
72%)
31% (16%, 45%) 42% (28%,
56%)
* based on case-series only and excluding Graboyes (as unclear if TORS or TLM).
Table 3
Tumour site identification rates by TORS/TLM and by lingual tonsillectomy following different diagnostic techniques.
Preliminary investigation Cases with no suspicious findings on preliminary investigations Cases with Suspicious findings on preliminary investigations
Identification by TORS/TLM Identification by lingual
tonsillectomy
Identification by TORS/TLM Identification by lingual tonsillectomy
N cases (n
studies)
Pooled %
(95% CI)
N cases (n
studies)
Pooled % (95%
CI)
N cases (n studies) Pooled % (95%
CI)
N cases (n
studies)
Pooled % (95% CI)
Physical exam 321/416 (14
studies)
79 (73, 85) 168/297 (12
studies)
59 (49, 68) 1/105 (6 studies) 100% (1 patient) 1/105 (6
studies)
100% (1patient)
Conventional imaging (CT/
MRI)
258/320 (10
studies)
82 (76, 89) 131/233
(8 studies)
59 (47, 71) 5/9
(1 study)
55.6% (5/9
patients)
0/42
(3 studies)
N/A
PET/CT 221/294
(12 studies)
75 (66, 84) 95/157
(7 studies)
61 (54–69) 50/61
(6 studies)
92 (75, 100) 6/6
(2 studies)
100 (70–100)
PE/DI/PET-CT 62/85
(4 studies)
73 (64, 83) 45/72
(3 studies)
64 (50, 79) 32/41
(3 studies)
84 (63, 98) 17/29
(2 studies)
61 (41, 80)
EUA with biopsy 53/80
(6 studies)
69 (57, 82) 52/97
(4 studies)
62 (40, 84) 12/14 patients (2
studies)
0.89 (63,100) 2/3
(1 study)
67% (2/3
patients)
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(by either palatine or lingual tonsillectomy) in cases with a negative
physical examination was 79% (95% CI 73–85%). In these cases, TBM
identified the primary site in 59% (95%CI 49–68%). In patients with
negative physical examination and negative conventional diagnostic
imaging, the primary was identified by transoral surgery in 82% (95%
CI 76, 89%) of cases, with TBM also identifying 59% (95% CI 47, 71%)
of cases. In patients with a negative PETCT scan, transoral surgery
identified the primary in 75% (95% CI 66, 84%) cases; in these cases,
TBM identified the primary in 61% (95% CI 54, 69%) of cases.
Identification rates after negative examination, conventional and
PETCT imaging, and then after panendoscopy TBM identified the pri-
mary site in 62% of cases (Table 4).
Effect of Human papillomavirus causation
There were 5 studies where HPV cases comprised 90% or more of
the cases. In these the a primary was identified in the tongue base in
53% (95% CI=42–65%) of cases, and in the palatine tonsils in 30%
(95%CI=19–48%)cases. However, heterogeneity between studies was
high (I2= 67% and 90% respectively, limiting interpretation.
Utility of frozen section
Frozen section was utilised in 9 studies only. One study used frozen
section and excluded patients with positive findings on frozen section
from the reported results [18]. Eight studies used frozen section to di-
rect margin control if positive and/or resection of the opposite side of
the tongue base if negative [7,8,11,20,21,23,29,25]. In the eight studies
utilizing frozen section, the rate of identification in the tongue base was
61% (95% CI 36, 61).
Adverse events and length of stay
Adverse events described in the studies are shown in Table 4. In
total, 8 studies reported all expected adverse events and a total of 8
reported on selected adverse events. Mortality rates were most com-
prehensively reported: in 15 studies, there was only one death reported
occurring post procedure secondary to a cardiopulmonary event. Hae-
morrhage was reported by 13 studies, with 19/387 (4.9%) patients
experiencing bleeding as a complication of the procedure
[5,8,9,12,14,17–21,24,25,27]. Thirteen studies reported on tra-
cheostomy rates; no tracheostomies were placed in 220 patients
[8–12,14,17,18,21,22,24,25,27]. Two patients out of 300 (0.7%) re-
quired a gastrostomy [12,18] Other complications, each occurring in a
single patient, were: Tongue sensitivity, tongue swelling, chest infec-
tion, pulmonary embolus, readmission due to pain and dehydration and
odynophagia secondary to candida [5,14,17,21,24] Only four studies
described the mean length of stay, which varied between 1.4 and
6.3 days [21–24].
Discussion
Overall, in this meta-analysis, the proportion of primary tumours
identified in the lingual or palatine tonsils, using TORS or TLM, ranged
from 44–94%, with a pooled proportion of 78%, in those patients where
the primary was not identified by previous investigations. Identification
of a base of tongue primary by TBM occurred in 53% of reported cases,
whilst identification of a tonsil primary occurred in 31% of cases. In
those cases where TBM was performed following negative diagnostic
Fig. 2. Pooled rates of identification rates by transoral surgery overall and by TORS and TLM separately.
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Fig. 3. Pooled rates of identification by TORS and TLM for lingual tonsillectomy.
Table 4
Table of adverse events following TORS and TLM.
Author Tracheostomy Haemorrhage Gastrostomy Other Deaths Length of stay Total no. of
complications
Mehta 0 0 1 0 0 NR 1 (10%)
Channir 0 1 0 1-Tongue
sensitivity
1- P.E.
0 NR 3 (23%)
Patel NR 4 0 1- tongue swelling 0 NR 5 (10.6%)
Winter 0 2 0 1- chest infection 0 NR 3 (9.3%)
Karni NR NR NR 0 0 NR NR
Durmus 0 NR 0 0 0 NR 0
Nagel 0 1 0 0 0 NR 1 (2.7%)
Geltzeiler 0 2 1 0 0 NR 3 (6%)
Hatten NR 3 0 1-Cardiopulmonary event
post-procedure
NR 3 (5%)
Graboyes NR 6 NR 0 0 NR 6 (9.2%)
Byrd 0 0 0 1-Pain and
dehydration
0 1.4 days (mean) 1 (4.5%)
Khan/Kass 0 NR NR 0 0 1.7 days (mean range 1–3) 0
Abuzeid 0 0 0 0 0 NR 0
Mourad 0 NR NR 0 0 NR 0
Blanco NR NR NR 0 NR 2.5 days (mean) 0
Krishnan 0 0 0 1-Candida -
odynophagia
NR 6.3 days (mean) –four had neck
dissection on same admission
lengthening overall time of stay
1 (3.7%)
Patel 0 0 0 NR 0 NR NR
Khan NR NR NR NR NR NR NR
Wolford 0 0 0 NR NR NR 0
Newman NR NR NR NR 0 NR NR
Kuta NR NRR NR NR NR NR NR
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investigations (conventional imaging, PETCT, EUA and palatine ton-
sillectomy), the detection rate of the primary in the tongue base was
even higher, with a pooled identification rate of 78%, demonstrating
the considerable additional benefit of TBM in the diagnostic work up of
cases of unknown primary of the head and neck. It should be noted
however that these patients have already been highly selected by the
fact that previous conventionl and PET imaging, and in some cases
examination under anaesthetic, have not identified the tumours.
Our review also highlights that there is still large variation in the
diagnostic workup of occult primaries e.g. 43% performed a CT, 40%
requested an MRI, 81% undertook a PETCT, and 5% performed an USS.
Only 12.2% had palatine tonsillectomy prior to TBM by TORS. Whilst
MRI and CT scans provide an abundance of information, its uses can be
limited when the primary is small [30,31]. PETCT may be useful in
these situations; however; it still fails to detect tumours less than 8 to
10mm in diameter [32]. The detection rate of the unknown primary
using PETCT has been reported as 44% with a sensitivity and specificity
of 97% and 68% respectively [31,33]. A false positive rate of between
20 and 40% has been described in the literature for PETCT in the
identification of the unknown primary [34]. Our meta-analysis found
that in cases where the PETCT scan was negative, palatine and lingual
tonsillectomy identified a primary site in a further 75% of cases. This
demonstrates the additional benefit of palatine and lingual tonsil-
lectomy following negative PETCT scans for this indication.
The efficacy of TBM varied with the timing of its application within
the diagnostic pathway. TBM yielded the highest findings when applied
at the end of the diagnostic pathway, after conventional imaging,
PETCT, EUA and tonsillectomy were negative. The improvement in
efficacy and detection rate should be weighed against the cost of an
additional operative procedure, separate to the preceding EUA and
tonsillectomy, and the potential delay in definitive treatment. A small
study demonstrated that using TBM at the end of the pathway as a
separate procedure when tonsillectomy was negative, was the most
cost-effective scenario [19]. This requires further corroboration.
Our study found that the identification rates between TORS and
TLM differed, 74% and 91% respectively. Whilst this suggests that TLM
may be more effective at identifying the primary tumour, the under-
pinning evidence is limited, with only three studies reporting on a total
of only 81 patients. The higher detection rate may therefore reflect
selection bias in the reporting of TLM studies and the more limited
availability of centres with TORS expertise compared to TLM.
Results were not reported in studies by HPV status. The rates of
detection of the primary in series almost completely comprised of HPV
+ cases were similar to that the overall pooled cohort. However the
heterogeneity between the limited number of studies was very high,
limiting interpretation and conclusions.
The use of frozen section at the time of the procedure to confirm the
primary site, and guide the procedure, does not appear to improve yield
considerably. However, there was lack of clarity regarding the re-
porting of this in studies, and the utility of frozen section needs further
study.
The most common surgical complication described by both the
TORS and TLM studies was haemorrhage post surgery. Since, two stu-
dies out of three reporting on TLM failed to describe their complica-
tions; a direct comparison of this complication between the two
methods was not possible. Gastrostomy–dependency is often quoted as
one of the major drawbacks of chemoradiotherapy Durmus et al de-
scribed a rate of 45% requiring a gastrostomy temporarily following
TORS, with 1 patient remaining gastrostomy dependent [35]. Our
systematic review found that the gastrostomy rate was 0.18% following
TORS or TLM for this indication, and the tracheostomy rate was 0%.
A few studies have reported on the functional quality of life fol-
lowing TORS and TLM for the occult primary. This is an important
factor when considering transoral surgery as a potential tool in the
diagnosis pathway. One study considered four domains: Speech, eating,
aesthetics and social disruption. Overall they found that low scores and
deterioration were detected in all four domains in the first three
months. However, all domains except eating returned to pre-operative
levels by 12months [35]. A further study reported difficulties with
eating and social disruption at 12months whilst problems with speech
and aesthetics returned to pre-operative levels [36].
The main strengths of this study lie in it being the largest reported
meta-analysis, with a total of 556 cases from 21 studies. The previous
systematic review by Fu et al in 2016 looked at 8 studies and a total of
139 patients. In addition, our study looked at the role of mucosectomy
in different workup pathways and with different combinations of di-
agnostic techniques, including physical examination and conventional
radiological and PETCT workup.
The main limitation of this study was that the underlying data was
reported in case reports and case series. As a result, there was sig-
nificant variability in diagnostic work-up, and there is likely to be
considerable variation in surgical technique. It is also highly likely that
there is bias in case selection. There is currently a prospective trial
recruiting in Toronto assessing the efficacy of TORS in identifying small
oropharyngeal carcinomas. Larger, prospective multicentre, and pos-
sibly multi-national, studies are needed. These must ensure better
standardisation of techniques both diagnostically and in terms of
treatment. Another limitation is that five studies did not report com-
plication rates and 8 did not state the incidence of some of the potential
complications. Therefore, it is possible that there is an underreporting
of the complication rates.
Identification of the primary mucosal lesion in cases of cervical
metastases of unknown origin can play an important role in the man-
agement of the patient’s disease. Detection of the primary may poten-
tially completely obviate the need for radiotherapy resulting in single
modality treatment. Alternatively, it may result in the reduction of the
dose of radiotherapy given to the contralateral uninvolved tonsil and
neck, which may lead to reduced toxicity. Furthermore in some studies,
patients whose site has been identified demonstrated significantly
better survival outcomes compared to those patients where no primary
site has been identified [7,37,38,39].
Finally, there are still several unanswered questions regarding the
timing, techniques and cost-effectiveness of TBM. Futhermore, the ef-
fect of HPV status on the efficacy of TBM should be examined and re-
ported, as this may have an implication for the cost-effectiveness of the
procedure. Additionally, no studies to date have looked at the psy-
chological impact on patients when a series of investigations are per-
formed, only to conclude that this is an unknown primary. Prospective,
and especially randomised, trials examining the use, quality of life
outcomes and cost effectiveness of TBM by transoral surgery in this
setting are much needed.
Conclusion
Overall, this systematic review confirms the high efficacy of TBM by
TORS and TLM in identifying the site of the primary in cases of head
and neck cancer, especially in cases where the primary site has not been
identified by other diagnostic methods. Data remains mainly from case
series, and prospective randomised data on cost effectiveness and
quality of life outcomes is much needed.
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